Cerebra

About Cerebra

CerebraAI operates at the intersection of artificial intelligence and emergency medicine, focusing on the critical window for stroke diagnosis. The company was established in 2018 in Kazakhstan by Founder and CEO Doszhan Zhussupov and has since relocated its headquarters to Palo Alto, California, to better access the U.S. market. Zhussupov's journey began after selling his shares in a previous MedTech venture, Med365.info, and investing in an AI team that included neurologists Dr. Alma Zhussupova and Dr. Meruyert Saifullakyzy, who brought deep expertise in stroke care. The company is a portfolio member of accelerators at Stanford (StartX) and UC Berkeley (Health Engine Accelerator).

The core of CerebraAI's business is a cloud-based AI platform designed to analyze non-contrast computed tomography (NCCT) brain scans for signs of ischemic and hemorrhagic strokes. This is particularly significant because NCCT scans are widely available in most hospital emergency departments but detecting early-stage ischemic strokes on them with the human eye is notoriously difficult. The technology aims to provide diagnoses in minutes, a substantial improvement that helps clinicians act within the crucial 4.5-hour therapeutic window for treatment. The system generates personalized AI images of a patient's pseudo-healthy brain to better highlight abnormalities for physicians. It serves healthcare professionals, including radiologists and neurologists, in hospitals and emergency departments.

The product is delivered as a software solution accessible via a web platform or a mobile application for iOS and Android. When a scan is performed, it is uploaded to CerebraAI's secure cloud for immediate analysis by the deep learning algorithms. Clinicians then receive a detailed summary and visual overlays on their mobile devices, enabling faster and more informed treatment decisions. The business model involves offering the platform in multiple tiers, including options for academic use, mid-sized hospitals, and custom enterprise solutions for large health networks. The company has analyzed over 150,000 patient scans and is trusted by more than 50 hospitals across several countries.